Survodutide
An experimental weekly GLP-1 and glucagon dual agonist from Boehringer Ingelheim, studied for obesity and fatty liver disease (MASH).
- Evidence
- Ongoing clinical research
- Half-life
- Days
- Sources
- 3 cited
Is survodutide FDA-approved?
Investigational. Not FDA-approved.
Overview
In a 46-week phase 2 trial, adults with obesity on the highest dose lost about 15% of body weight, versus about 3% on placebo. In a phase 2 MASH trial, liver disease improved in up to 62% of people, versus 14% on placebo. Phase 3 trials for obesity and MASH followed, with the first obesity results published in 2026.
How it works
GLP-1 action lowers appetite. Glucagon action raises energy use and helps the liver burn stored fat, which is why it's being studied for fatty liver.
How long does survodutide stay in the body?
Long enough for once-weekly shots in trials.
What it's studied for
- Obesity
- Fatty liver disease (MASH)
- Heart outcomes
Reported side effects
- Nausea, vomiting, diarrhea, constipation (common, mostly during dose increases)
Related: CagriSema, Mazdutide, Cagrilintide, Orforglipron.
Sources
The studies and prescribing labels this page is written from.
- Survodutide for obesity: a dose-finding phase 2 trial. Lancet Diabetes Endocrinol, 2024 PubMed
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med, 2024 PubMed
- Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med, 2026 PubMed
